PEGylated Interferon Beta-1a: Meeting an Unmet Medical Need in the Treatment of Relapsing Multiple Sclerosis (Q37788252)

23 August 2017

title

PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis (English)

1 reference

23 August 2017

PEGylated Interferon Beta-1a: Meeting an Unmet Medical Need in the Treatment of Relapsing Multiple Sclerosis (English)

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

11 July 2024

0 references

1 reference

Robert Blake Pepinsky

2

1 reference

23 August 2017

Margot Brickelmaier

3

1 reference

23 August 2017

Xiao Hu

5

1 reference

23 August 2017

Kenneth Olivier

6

1 reference

23 August 2017

Michaela Lerner

7

1 reference

23 August 2017

Larisa Miller

8

1 reference

23 August 2017

Mary Crossman

9

1 reference

23 August 2017

Ivan Nestorov

10

1 reference

23 August 2017

Meena Subramanyam

11

1 reference

23 August 2017

Stacy Hitchman

12

1 reference

23 August 2017

Gabrielle Glick

13

1 reference

23 August 2017

Sandra Richman

14

1 reference

23 August 2017

Shifang Liu

15

1 reference

23 August 2017

Ying Zhu

16

1 reference

23 August 2017

Gudarz Davar

18

1 reference

23 August 2017

Darren P. Baker

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20836711

11 July 2024

Robert S. Gronke

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20836711

11 July 2024

Michael A. Panzara

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20836711

11 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20836711

11 July 2024

publication date

1 October 2010

1 reference

full work available at URL

23 August 2017

http://www.liebertpub.com/doi/full-xml/10.1089/jir.2010.0092

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

http://www.liebertpub.com/doi/pdf/10.1089/jir.2010.0092

11 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Journal of Interferon and Cytokine Research

11 July 2024

published in

1 reference

23 August 2017

volume

30

1 reference

23 August 2017

issue

10

1 reference

23 August 2017

page(s)

777-785

1 reference

Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Expression, purification, and characterization of rat interferon-beta, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters

11 July 2024

2

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Characterization of a soluble ternary complex formed between human interferon-beta-1a and its receptor chains

11 July 2024

3

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

11 July 2024

4

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.

11 July 2024

5

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation

11 July 2024

6

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

The interleukin (IL)-2 family cytokines: survival and proliferation signaling pathways in T lymphocytes

11 July 2024

7

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Interferon‐β Is a Potent Promoter of Nerve Growth Factor Production by Astrocytes

11 July 2024

10

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Ligand-induced association of the type I interferon receptor components

11 July 2024

11

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Direct binding to and tyrosine phosphorylation of the alpha subunit of the type I interferon receptor by p135tyk2 tyrosine kinase

11 July 2024

12

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.

11 July 2024

15

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

11 July 2024

16

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Increased CD80( ) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy

11 July 2024

17

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

IFN-beta1a modulates the expression of CTLA-4 and CD28 splice variants in human mononuclear cells: induction of soluble isoforms

11 July 2024

18

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

11 July 2024

19

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Structural and biologic characterization of pegylated recombinant IFN-alpha2b

11 July 2024

20

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice

11 July 2024

21

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

What do we know about the mechanism of action of disease-modifying treatments in MS?

11 July 2024

22

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

11 July 2024

23

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis

11 July 2024

24

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Interferon-β downregulates interferon-γ-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells

11 July 2024

25

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

11 July 2024

26

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

11 July 2024

27

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Effects of interferon-beta on microglial functions as inflammatory and antigen presenting cells in the central nervous system

11 July 2024

29

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein

11 July 2024

30

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event

11 July 2024

31

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Development of pegylated interferons for the treatment of chronic hepatitis C.

11 July 2024

32

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Functional subdomains of STAT2 required for preassociation with the alpha interferon receptor and for signaling

11 July 2024

33

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

11 July 2024

34

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Immunomodulatory effects of interferon beta-1a in multiple sclerosis

11 July 2024

35

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma

11 July 2024

36

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys

11 July 2024

37

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

11 July 2024

38

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis autoimmune diseases

11 July 2024

39

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis

11 July 2024

40

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Decreased integrin gene expression in patients with MS responding to interferon-beta treatment

11 July 2024

41

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Timing of IFN-β Exposure during Human Dendritic Cell Maturation and Naive Th Cell Stimulation Has Contrasting Effects on Th1 Subset Generation: A Role for IFN-β-Mediated Regulation of IL-12 Family Cytokines and IL-18 in Naive Th Cell Differentiation

11 July 2024

42

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection

11 July 2024

43

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis

11 July 2024

44

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

The human interferon alpha/beta receptor: characterization and molecular cloning

11 July 2024

45

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Clinical trials of interferons in multiple sclerosis. What have we learned?

11 July 2024

46

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Actions of cytokines on the immune response and viral interactions: an overview

11 July 2024

48

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Biophysical analysis of the interaction of human ifnar2 expressed in E. coli with IFNalpha2.

11 July 2024

49

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

IFN-alpha regulates Toll-like receptor-mediated IL-27 gene expression in human macrophages

11 July 2024

50

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Alpha/beta interferon is a neuronal growth factor

11 July 2024

51

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients

11 July 2024

52

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

11 July 2024

53

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

11 July 2024

54

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C.

11 July 2024

56

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta

11 July 2024

58

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta)

11 July 2024

60

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity

11 July 2024

61

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Differences in Activity between α and β Type I Interferons Explored by Mutational Analysis

11 July 2024

62

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up

11 July 2024

63

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis

11 July 2024

64

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

The 'Immunological-Synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-β

11 July 2024

66

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Interferon-beta therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis

11 July 2024

67

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin.

11 July 2024

68

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

11 July 2024

69

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Interferon-β downregulates expression of VLA-4 antigen and antagonizes interferon-γ-induced expression of HLA-DQ on human peripheral blood monocytes

11 July 2024

70

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Interferons: biochemistry and mechanisms of action

11 July 2024

71

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Alpha and beta interferons and their receptor and their friends and relations.

11 July 2024

72

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta

11 July 2024

73

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Interferon-beta differentially regulates expression of the IL-12 family members p35, p40, p19 and EBI3 in activated human dendritic cells

11 July 2024

74

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

A protein tyrosine kinase in the interferon alpha/beta signaling pathway

11 July 2024

75

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

11 July 2024

76

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Direct association of STAT3 with the IFNAR-1 chain of the human type I interferon receptor

11 July 2024

77

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

11 July 2024

78

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Interferon beta in the treatment of multiple sclerosis: mechanisms of action

11 July 2024

79

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis

11 July 2024

80

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

Peginterferon alfa-2a in patients with chronic hepatitis C.

11 July 2024

81

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0092

11 July 2024

Identifiers

1 reference

release_bx5q2byxyjflrkzcjquq46vehi

23 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bx5q2byxyjflrkzcjquq46vehi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference